The official blog of the Lung Institute.
Tampa, Florida, Jan. 30, 2018 – Lung Institute, a provider of cellular therapy therapy to patients with developing or developed COPD and under the medical management company Regenerative Medicine Solutions, today announced it has earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Health Care Accreditation by demonstrating continuous compliance with its nationally recognized standards. An innovative leader in regenerative medicine, the Lung Institute’s receipt of the Joint Commission’s Gold Seal of Approval® is a symbol of high quality that reflects an organization’s commitment to providing safe and effective patient care.
Dedicated to providing cellular therapies for lung disease and offering patients a more effective way to address pulmonary conditions, the Lung Institute underwent a rigorous, unannounced onsite survey from Dec. 4-6, 2017, to receive this accreditation. During the review, a Joint Commission surveyor with expertise in ambulatory health care evaluated compliance with ambulatory care standards related to a variety of areas, including coordination of care, monitoring for procedures that involve use of sedation or anesthesia, infection prevention and control, management of medications, and patient education and training.
“As an organization that is centered around upholding the highest level of patient care, the Lung Institute is pleased to receive accreditation from The Joint Commission, the premier health care quality improvement and accrediting body in the nation,” said Jimmy St. Louis, founder and CEO of Regenerative Medicine Solutions. “Our team is passionate and committed to a patient-first approach and bringing together leaders in the regenerative medicine and wellness communities to create new and innovative treatment options that improve the lives of those suffering from chronic lung disorders.”
Established in 1975, The Joint Commission’s Ambulatory Health Care Accreditation Program encourages high-quality patient care in all types of freestanding ambulatory care facilities. Today the Ambulatory Health Care Accreditation Program serves 2,100 ambulatory care providers with more than 8,500 sites of care which, in turn, serve more than 83 million patient visits annually.
“Joint Commission accreditation provides ambulatory care organizations with the processes that contribute to improvements in a variety of areas from the enhancement of staff education to the demonstration of leading practices within the ambulatory setting,” said Michael Kulczycki, M.B.A., CAE, executive director, Ambulatory Health Care Accreditation Program, The Joint Commission. “We commend the Lung Institute and its staff for achieving this pinnacle, demonstrating a commitment to patient safety and quality. Your passion, dedication and tenacity can ultimately improve patient care. Thank you for your commitment to patient safety and entrusting The Joint Commission to assist you.”
The Joint Commission’s ambulatory health care standards are developed in consultation with health care experts and providers, measurement experts, and patients. The standards are informed by scientific literature and expert consensus to help organizations measure, assess and improve performance.
The Joint Commission
Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission accredits and certifies more than 21,000 health care organizations and programs in the United States. An independent, nonprofit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.
About the Lung Institute
The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date the organization has treated more than 4,600 patients with a nearly 95 percent satisfaction rate. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Nashville, Tenn., Scottsdale, Ariz., Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 382-8095.
Kwittken for RMS